Show simple item record

dc.contributor.authorVormoor, B
dc.contributor.authorVeal, GJ
dc.contributor.authorGriffin, MJ
dc.contributor.authorBoddy, AV
dc.contributor.authorIrving, J
dc.contributor.authorMinto, L
dc.contributor.authorCase, M
dc.contributor.authorBanerji, U
dc.contributor.authorSwales, KE
dc.contributor.authorTall, JR
dc.contributor.authorMoore, AS
dc.contributor.authorToguchi, M
dc.contributor.authorActon, G
dc.contributor.authorDyer, K
dc.contributor.authorSchwab, C
dc.contributor.authorHarrison, CJ
dc.contributor.authorGrainger, JD
dc.contributor.authorLancaster, D
dc.contributor.authorKearns, P
dc.contributor.authorHargrave, D
dc.contributor.authorVormoor, J
dc.date.accessioned2017-03-24T14:15:24Z
dc.date.issued2017-06
dc.identifier.citationPediatric blood & cancer, 2017, 64 (6)
dc.identifier.issn1545-5009
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/494
dc.identifier.eissn1545-5017
dc.identifier.doi10.1002/pbc.26351
dc.description.abstractAurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectLeukemia
dc.subjectAcute Disease
dc.subjectUrea
dc.subjectBenzimidazoles
dc.subjectNeoplasm Proteins
dc.subjectProtein Kinase Inhibitors
dc.subjectMaximum Tolerated Dose
dc.subjectAdolescent
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectInfant
dc.subjectFemale
dc.subjectMale
dc.subjectAurora Kinases
dc.titleA phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
dc.typeJournal Article
dcterms.dateAccepted2016-10-07
rioxxterms.versionofrecord10.1002/pbc.26351
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfPediatric blood & cancer
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical PD Biomarker Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical PD Biomarker Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical PD Biomarker Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical PD Biomarker Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume64
pubs.embargo.termsNot known
icr.researchteamClinical PD Biomarker Groupen_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
dc.contributor.icrauthorSwales, Karenen
dc.contributor.icrauthorBanerji, Udaien
dc.contributor.icrauthorTurner, Lydiaen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record